Drug intelligence / Profile preview

sabin-strain inactivated polio vaccine

Development stage: Phase 4
Lead developer: Batavia Biosciences
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous, Intradermal

Overview

Sabin-strain inactivated polio vaccine (sIPV) is a vaccine developed to prevent poliomyelitis. It utilizes inactivated Sabin poliovirus strains and is manufactured using Batavia Biosciences' proprietary HIP-Vax process. Batavia Biosciences received grant funding from the Bill & Melinda Gates Foundation for its development and contracted Valneva for the manufacturing of clinical trial lots. The vaccine is intended for use in developing countries.

Beyond the preview

Go deeper on sabin-strain inactivated polio vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sabin-strain inactivated polio vaccine.

Explore the full profile